Form 4: Apogee Therapeutics CFO Executes Planned Stock Sale

Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of common stock on May 1, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• CFO Jane Henderson sold a total of 2,000 shares of Apogee Therapeutics common stock.
• The sales were executed in three tranches at weighted average prices of $81.02, $82.60, and $83.16.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on September 2, 2025.
• Following these transactions, the reporting person retains beneficial ownership of 173,371 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement and does not signal a change in company fundamentals.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating the transaction was scheduled in advance rather than based on non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in future short-term price appreciation, though this was a planned divestment.

Risks

• Market volatility affecting the share price of Apogee Therapeutics.
• Reliance on Rule 10b5-1 plans does not eliminate the risk of negative market sentiment regarding insider selling activity.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard corporate governance practice for executives to manage personal liquidity and is generally viewed as neutral by institutional investors.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest or accusations of insider trading.
• The volume of shares sold represents a small fraction of the executive's total holdings, which is consistent with typical executive financial planning.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the executive's total equity stake.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, CFO, Rule 10b5-1